The Asia Pacific Human Insulin Market is projected to witness market growth of 3.8% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Human Insulin Market by country in 2023, and is projected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.57 billion by 2031. The Japan market is registering a CAGR of 3.2% during 2024-2031. Additionally, the India market would showcase a CAGR of 4.5% during 2024-2031.
Technological advancements in biotechnology have significantly transformed the insulin market, developing more effective and safer insulin analogs. These innovations have improved patient outcomes and driven market expansion by addressing some of the key limitations of traditional insulin therapies. Insulin analogs are modified insulin forms that mimic the body’s natural insulin release patterns. Unlike regular insulin, which has a standard action profile, insulin analogs can be engineered to have different onset times, peak activity periods, and durations of action. This enables the management of blood glucose levels to be more precise and adaptable.
Advances in genetic engineering and protein modification technologies have driven the development of these analogs. Scientists have developed molecules with enhanced pharmacokinetic properties by modifying the amino acid sequence of insulin, thereby improving their absorption, distribution, metabolism, and excretion profiles. These modifications have led to insulin analogs that are more effective in controlling blood glucose levels and offer a lower risk of adverse effects, such as hypoglycemia, a common and potentially dangerous side effect of insulin therapy.
The Asia Pacific region is experiencing a dramatic surge in diabetes cases, primarily Type 2 diabetes, fueled by urbanization, sedentary lifestyles, and dietary changes. This escalating patient population is driving a robust demand for insulin therapies, including human insulin. In Asia Pacific, diabetes affects more than 60% of the population, with China and India having the highest rates. According to the World Health Organization, in the Western Pacific, there are already more than 131 million diabetics, with 201 million expected by 2035. According to the National Library of Medicine, between 2000 and 2035, the proportion of diabetics is supposed to increase by 150% in South Asia. Several prominent government programs and initiatives address Australia's increasing demand for this insulin. The National Diabetes Services Scheme (NDSS), funded by the Australian government, provides subsidized access to diabetes-related products, including insulin, and supports diabetes education and management. The Australian National Diabetes Strategy 2016-2020 outlines a national framework for improving diabetes prevention, care, and research. This strategy emphasizes early detection, effective management, and reducing the impact of diabetes-related complications. Australia's Medicare system also provides coverage for diabetes management services, ensuring that insulin and other essential treatments are affordable and accessible to all Australians. Thus, the increasing prevalence of diabetes and rising government support for raising awareness of the disease are the leading factors driving the expansion of the regional market.
Based on Indication, the market is segmented into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Based on Product Type, the market is segmented into Pens, Syringes, and Others. Based on Type of Insulin, the market is segmented into Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific Human Insulin Market by country in 2023, and is projected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.57 billion by 2031. The Japan market is registering a CAGR of 3.2% during 2024-2031. Additionally, the India market would showcase a CAGR of 4.5% during 2024-2031.
Technological advancements in biotechnology have significantly transformed the insulin market, developing more effective and safer insulin analogs. These innovations have improved patient outcomes and driven market expansion by addressing some of the key limitations of traditional insulin therapies. Insulin analogs are modified insulin forms that mimic the body’s natural insulin release patterns. Unlike regular insulin, which has a standard action profile, insulin analogs can be engineered to have different onset times, peak activity periods, and durations of action. This enables the management of blood glucose levels to be more precise and adaptable.
Advances in genetic engineering and protein modification technologies have driven the development of these analogs. Scientists have developed molecules with enhanced pharmacokinetic properties by modifying the amino acid sequence of insulin, thereby improving their absorption, distribution, metabolism, and excretion profiles. These modifications have led to insulin analogs that are more effective in controlling blood glucose levels and offer a lower risk of adverse effects, such as hypoglycemia, a common and potentially dangerous side effect of insulin therapy.
The Asia Pacific region is experiencing a dramatic surge in diabetes cases, primarily Type 2 diabetes, fueled by urbanization, sedentary lifestyles, and dietary changes. This escalating patient population is driving a robust demand for insulin therapies, including human insulin. In Asia Pacific, diabetes affects more than 60% of the population, with China and India having the highest rates. According to the World Health Organization, in the Western Pacific, there are already more than 131 million diabetics, with 201 million expected by 2035. According to the National Library of Medicine, between 2000 and 2035, the proportion of diabetics is supposed to increase by 150% in South Asia. Several prominent government programs and initiatives address Australia's increasing demand for this insulin. The National Diabetes Services Scheme (NDSS), funded by the Australian government, provides subsidized access to diabetes-related products, including insulin, and supports diabetes education and management. The Australian National Diabetes Strategy 2016-2020 outlines a national framework for improving diabetes prevention, care, and research. This strategy emphasizes early detection, effective management, and reducing the impact of diabetes-related complications. Australia's Medicare system also provides coverage for diabetes management services, ensuring that insulin and other essential treatments are affordable and accessible to all Australians. Thus, the increasing prevalence of diabetes and rising government support for raising awareness of the disease are the leading factors driving the expansion of the regional market.
Based on Indication, the market is segmented into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Based on Product Type, the market is segmented into Pens, Syringes, and Others. Based on Type of Insulin, the market is segmented into Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- MannKind Corporation
- Lupin Limited
- Sanofi S.A.
- Novo Nordisk A/S
- Eli Lilly And Company
- Medtronic PLC
- Biocon Limited
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Pfizer, Inc.
Market Report Segmentation
By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
By Product Type
- Pens
- Syringes
- Others
By Type of Insulin
- Rapid-acting insulin
- Short-acting insulin
- Intermediate-acting insulin
- Others
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Providers
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Human Insulin Market by Indication
Chapter 5. Asia Pacific Human Insulin Market by Product Type
Chapter 6. Asia Pacific Human Insulin Market by Type of Insulin
Chapter 7. Asia Pacific Human Insulin Market by Distribution Channel
Chapter 8. Asia Pacific Human Insulin Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- MannKind Corporation
- Lupin Limited
- Sanofi S.A.
- Novo Nordisk A/S
- Eli Lilly And Company
- Medtronic PLC
- Biocon Limited
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Pfizer, Inc.
Methodology
LOADING...
